Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board
Former President and CEO of Roche Molecular Systems and Member of Roche’s Global Diagnostic Executive Committee BERKELEY, Calif. and MAINZ, Germany, Nov. 11, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Heiner Dreismann to […]
Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’
Flagship product ‘ColoAlert’ provides a unique, life-saving early detection test for colorectal cancer European registration completed and commercial rollout underway across multiple territories FDA clinical study process to be launched for U.S. regulatory approval BERKELEY, US – MAINZ, Germany – NOVEMBER 8, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular […]
MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market
BERKELEY, US – MAINZ, Germany – NOVEMBER 5, 2021 — Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announces that its shares have commenced trading today on the Nasdaq Capital Market under the ticker symbol “MYNZ”. On November 4, 2021, the Company […]
